Can CBD tame Self-Harm in kids with severe developmental disorders?
NCT ID NCT07564245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test whether cannabidiol (Epidyolex) can reduce severe self-injuries in 21 children aged 5 to 17 with neurodevelopmental disorders. Participants will receive increasing doses of oral cannabidiol over 28 days, then a steady dose for 35 more days. The main goal is to see if the frequency of self-injuries drops by at least 30% after 63 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cannabidiol (Epidyolex)
- What this could lead to
- If it works, this could point toward a new treatment option for severe self-injuries in children with neurodevelopmental disorders, potentially reducing harm and improving quality of life.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply broadly. Cannabidiol may cause side effects like drowsiness or liver issues, and the treatment might not reduce self-injuries as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURODEVELOPMENTAL DISORDERS WITH SEVERE SELF-INJURIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Necker Enfants malades
Paris, Île-de-France Region, 75015, France
-
Hôpital Pitié-Salpêtrière
Paris, Île-de-France Region, 75013, France